The diagnostic value of serum CA19-9, CEA and CA125 in patients with the benign and malignant diseases of & nbsp;pancreatic
Objective To investigate the value of serum CA19-9, CEA and CA125 in diagnosing pancreatic cancer(PC) and chronic pancreatitis(CP). Methods Electrochemiluminescence immunoassay(ECL) was used to detected the peripheral serum levels of CA19-9, CEA and CA125 in 60 patients with pancreatic cancer(PC group), 60 patients with chronic pancreatitis(CP group) and 60 healthy individuals(control group). The comparison and analysis are made on the value of serum tumor markers in the diagnosis of pancreatic cancer by application of single and joint assay of CA19-9, CEA and CA125. Results The serum levels of CA19-9, CEA and CA125 in PC group were significantly higher than those in CP group and control group(P <0.01). CA19-9, CEA and CA125 were not significantly different between CP group and control group(P >0.05). The sensitivities of CA19-9, CEA and CA125 in patients with pancreatic cancer were 82.14%, 47.36% and 37.4%, while the specificities were 53.26%, 61.26% and 63.15%. The sensitivity and specificity of joint detection of CA19-9, CEA and CA125 were 93.84% and 95.68%. Conclusion The joint detection of CA19-9, CEA and CA125 can improve the diagnostic value of pancreatic cancer and may be helpful in the differential diagnosis of pancreatic cancer.
CA19-9CEACA125The benign and malignant diseases of pancreatic
NETL
NSTL
万方数据
维普
